NPT-189 by Proclara Biosciences for Primary Systemic Amyloidosis: Likelihood of Approval
NPT-189 is under clinical development by Proclara Biosciences and currently in Phase I for Primary Systemic Amyloidosis.
United States United Kingdom Proclara Biosciences Globaldata Pharmaceutical Intelligence Center Primary Systemic Primary Systemic Amyloidosis
Source: pharmaceutical-technology.com